2024-513802-77-00已完成3 期
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)
Centre Hospitalier Universitaire Rouen, Centre Hospitalier Universitaire Rouen6 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2024年5月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 6
- 主要终点
- Partial remission at 6 months. In case of bilateral involvement, the eye with the most severe involvement will be the eye chosen for the study.
研究概览
简要总结
To evaluate the efficacy of baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis multi-refractory to two lines of biotherapy (anti-TNF alpha and tocilizumab) after 6 months of treatment
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of non-anterior non-infectious uveitis refractory to two lines of biotherapy (anti-TNF alpha and tocilizumab). Refractory uveitis is defined as: a. Either active uveitis, namely: anterior chamber inflammation >2+ [Tyndall, SUN scale (1)] and/or vitreous inflammation >2+ [Vitreous Haze, SUN scale (1)] and/or the presence of retinal vasculitides and/or the presence of cystoid macular edema (central macular thickness greater than strictly 300 μm measured on optical coherence tomography, associated with visualization of intraretinal logettes). b. or inactive uveitis but with corticosteroid dependence ≥ 10 mg/day for at least 3 months.
- •Need for discontinuation of biotherapy and conventional immunosuppressants (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) for at least 10 days prior to the inclusion date.
- •Patient of legal age who has read and understood the information letter and signed the consent form.
- •Patient affiliated to a social security plan.
- •Patient under 65 years old
- •Female: a. Of childbearing age (defined by the CTFG as fertile, post-menarche to post-menopause, except in cases of permanent infertility): Using effective contraception (estrogen-progestin or intrauterine device or tubal ligation) for at least 4 weeks prior to inclusion, during treatment, and up to 1 week after cessation of treatment And, Presenting a negative urine pregnancy test at inclusion; b. Surgically infertile: no ovaries and/or uterus and/or bilateral salpingectomy; c. Menopausal: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit)
- •Negative quantiferon less than 6 months old (6 months included) and normal chest x-ray less than 3 months old (3 months included) or positive quantiferon in patients with a history of previously treated latent TB according to current recommendations
- •HIV, HCV and HBV serology with no active infection, less than 1 month old (1 month included)
排除标准
- •Isolated anterior uveitis
- •Previous treatment with JAK inhibitors
- •Intraocular corticosteroid injection (subconjunctival or laterobulbar) within 1 month prior to inclusion or placement of an intravitreal corticosteroid implant within 3 months prior to inclusion.
- •Need for treatment with a biotherapy (anti-IL6, anti-IL6 receptor, anti-IL1, anti-IL12/IL23 anti-IL17, anti-BAFF) for extra-ocular involvement, during the entire study period.
- •Treatment with OAT3 inhibitors with high inhibitory potential such as probenecid, leflunomide, teriflunomide
- •Vaccination with a live vaccine or live attenuated vaccine within 15 days prior to inclusion
- •Risk factor for developing a malignancy (patient has or has had a malignancy)
- •Personal history of venous thromboembolic disease.
- •Presence of a hereditary coagulation disorder
- •Risk factors for major cardiovascular events (such as a history of heart attack or stroke)
- •Smokers or Former Long-term smokers
- •Infectious uveitis
- •Pregnant or parturient or breastfeeding woman or lack of proven contraception
- •Obese patient with a body mass index ≥ 40 kg/m2
- •Hemoglobin < 8 g / dl
- •Platelet count <100,000 / mm3 or >500,000 / mm3
- •Neutrophil count <1000 / mm3, lymphocyte count <500/mm
- •Renal impairment with clearance <30 ml/min.
- •Severe hepatic impairment.
- •Allergy to fluorescein
- •Person deprived of liberty by an administrative or judicial decision or person placed under safeguard of justice / sub guardianship or curatorship.
- •Patient who has participated in another drug trial within 3 months prior to the start of the study.
- •Severe uveitis threatening the visual prognosis and requiring emergency treatment with intravenous corticosteroids
- •Initial visual acuity > 1.3 LogMAR in at least one eye.
- •Corneal or lens opacity that prevents fundus visualization or may require cataract surgery during the study.
- •Contraindication to baricitinib (OLUMIANT 2 and 4 mg film-coated tablets): Hypersensitivity to the active substance or to any of the excipients.
- •Contraindication to mydriasis.
- •Refractory glaucoma in either eye.
- •Monophthalmic patient.
结局指标
主要结局
Partial remission at 6 months. In case of bilateral involvement, the eye with the most severe involvement will be the eye chosen for the study.
Partial remission at 6 months. In case of bilateral involvement, the eye with the most severe involvement will be the eye chosen for the study.
次要结局
- Partial remission at 1 month, 3 months of treatment, according to the same parameters as defined for the primary endpoint.
- Median change in visual acuity (LogMAR) at 1 month, 3 months and 6 months of treatment compared to baseline ophthalmologic assessment
- Slit-lamp measurement of median change in anterior chamber inflammation according to the Tyndall, SUN (1) scale at 1 month, 3 months and 6 months of treatment compared to baseline ophthalmologic assessment
- Slit-lamp measurement of median change in vitreous inflammation according to the vitreous haze (SUN [1]) at 1 month, 3 months, and 6 months of treatment compared with the initial ophthalmologic evaluation.
- Fluorescein angiographic analysis of vasculitis lesions at 1 month, 3 months, and 6 months of treatment compared with the initial ophthalmologic evaluation
- Optical coherence tomography measurement of median change in central macular thickness at 1 month, 3 months, and 6 months of treatment compared with the initial ophthalmologic evaluation.
- Measurement of the number of patients with correction of cystoid macular edema measured by optical coherence tomography (cystoid macular thickness <300 μm and disappearance of intraretinal logettes) at 1 month, 3 months, and 6 months of treatment compared with the initial ophthalmologic assessment
- Measurement of median change in corticosteroid dosages at 1 month, 3 months, and 6 months of treatment compared with the initial ophthalmologic evaluation
- EvI and EvIG on baricitinib from initiation of treatment through 6 months of follow-up.
研究者
David MALLET
Scientific
Centre Hospitalier Universitaire Rouen
研究点 (6)
Loading locations...
相似试验
招募中
2 期
Inhibition of JAK enzymes in early stage joint inflammation2024-514026-23-00Universitaetsklinikum Erlangen AöR20
进行中（未招募）
1 期
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)Active non-anterior non-infectious uveitisMedDRA version: 22.1Level: LLTClassification code: 10066681Term: Acute uveitis Class: 10015919CTIS2024-513802-77-00Centre Hospitalier Universitaire Rouen33
招募中
2 期
Amping up With PemJAKNCT07283822Seda S. Tolu53
招募中
2 期
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)IgG4-related diseaseBehcet's disease2022-502968-20-02University Medical Center Utrecht60
招募中
1 期
JSKN022 in Subjects With Advanced Malignant Solid TumorsNCT07292402Jiangsu Alphamab Biopharmaceuticals Co., Ltd225